ICER Faces New Foe As Patient, Disability Alliance Takes Aims At Reports On Mayzent, Spravato
Executive Summary
Groups oppose use of quality-adjusted life year metric, noting ICER’s work is becoming more influential among payers. However, patient advocates do not suggest a uniform methodological alternative.
You may also be interested in...
Senate Finance Panel’s New Legislative Staffer Kaltenboeck Likes QALYs For Valuing Drugs
Anna Kaltenboeck joins the committee from Memorial Sloan Kettering’s health policy group, which has been an active participant in US drug pricing reform policy development and a critic of the biopharma industry, often through public commentary by its director, Peter Bach.
ICER’s Biopharma Members: Why They Joined And What They Get
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.
J&J's Spravato Set For EU Launches Soon
If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.